Prognostic factors in prostate cancer

Area of Science:

• Oncology
• Cancer Biology
• Pathology

Background:

• Prostate cancer (PCa) exhibits variable clinical behavior, necessitating accurate prediction of tumor progression risk.
• Understanding the roles of proliferation and apoptosis is crucial for distinguishing aggressive from indolent PCa.
• Biomarkers associated with proliferation and apoptosis may offer prognostic insights.

Purpose of the Study:

• To investigate the prognostic implications of proliferation and apoptosis biomarkers in prostate cancer.
• To assess the predictive value of p53 immunoreactivity for radioresistance.
• To evaluate early cellular response to castration therapy as a predictor of treatment outcome.

Main Methods:

• Immunoreactivity for p53, bcl-2, and Ki-67 was assessed and quantified in 186 PCa patients.
• Cause-specific survival (CSS) was correlated with biomarker indexes.
• p53 immunoreactivity was analyzed in relation to radiotherapy response in 60 PCa patients.
• Biopsies before and after castration therapy were examined for morphological changes and apoptotic index in advanced PCa.

Main Results:

• High Ki-67 index significantly predicted shorter CSS in both univariate and multivariate analyses.
• p53 immunoreactivity did not predict CSS or radioresistance.
• bcl-2 index was higher in prostatic intraepithelial neoplasia than in cancer, suggesting a role in early tumorigenesis, but lacked prognostic value.
• Increased apoptotic index and regressive morphology post-castration therapy correlated with clinical response in advanced PCa.

Conclusions:

• Ki-67 immunoreactivity is a potential prognostic factor for prostate cancer.
• The prognostic and predictive value of p53 and bcl-2 in PCa remains uncertain.
• Early cellular response to castration therapy, indicated by apoptosis and morphology, may predict treatment efficacy.